Frontlight ResearchEarly access
Active, not recruitingNo phase
Long-Term Study of CartiPRO for Knee Pain Due to Osteoarthritis or Cartilage Damage
Key facts
- Who runs it
- DALIM TISSEN Co., Ltd.
- Where
- South Korea5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 194 people, planned
- Started
- 3 Jul 2025
- Expected to end
- Jun 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- CartiPRO
- Synovian®
- Record updated
- 5 October 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 43 criteriaShow less
Who can take part
- Age 19 years and older
- Diagnosed with unilateral or bilateral knee osteoarthritis according to American College of Rheumatology (ACR) criteria, with at least 3 of the following 6 features:; Age ≥50 years; Morning stiffness <30 minutes; Crepitus on active motion; Bony tenderness; Bony enlargement; No palpable warmth
- Radiographic evidence of Kellgren-Lawrence grade I, II, or III osteoarthritis within 6 months prior to screening or at screening visit
- Weight-bearing pain Visual Analogue Scale (VAS) score ≥40 mm in at least one knee joint at screening
- Able to walk without assistive devices (walkers or canes), OR if using a walking aid routinely for past 6 months, able to continue using the same device throughout the study
- Able to understand and complete efficacy assessment questionnaires
- Willing and able to provide written informed consent
Who cannot take part
- History of myocardial infarction, congestive heart failure, other serious cardiac disease, or uncontrolled hypertension (≥140/90 mmHg despite treatment with ≥3 antihypertensive agents)
- Cancer diagnosis within 5 years prior to screening
- Surgical procedures (including arthroscopy) on target knee within 1 year (surgery on contralateral knee or hip may be exclusionary if it could affect target knee assessment)
- Intra-articular corticosteroid injection into target knee within 12 weeks
- Systemic corticosteroid use within 4 weeks (topical and inhaled corticosteroids permitted)
- Surgery or radiation therapy to knee joint within 12 weeks, or not fully recovered from side effects
- Immunosuppressive therapy (e.g., Cyclosporine A, Azathioprine) within 6 weeks
- Prohibited concomitant medications within 2 weeks (unless washout period is adequate)
- Anticoagulants (e.g., warfarin, NOACs), antiplatelet agents (e.g., aspirin >100 mg/day, clopidogrel; low-dose aspirin ≤100 mg/day permitted), thrombolytic agents (e.g., urokinase, alteplase), or Vitamin E >1000 IU/day within 2 weeks (unless adequate washout)
- Habitual use (≥3 months) of psychoactive drugs or narcotic analgesics that may affect pain perception
- Planned cell therapy or gene therapy to target joint
- Known hypersensitivity to investigational product or its components
- Women or men of childbearing potential unwilling to use acceptable contraception during study (acceptable methods: intrauterine device, tubal ligation, sterilization surgery, condom or diaphragm with spermicide, natural family planning)
- Chronic inflammatory joint disease (e.g., rheumatoid arthritis)
- Inflammatory joint disease (e.g., septic arthritis)
- Secondary knee osteoarthritis due to ochronosis, hemochromatosis, or systemic disease
- Painful musculoskeletal conditions (e.g., Sudeck's atrophy, Paget's disease, herniated intervertebral disc)
- Polyarticular disease with severe osteoarthritis in other joints (e.g., hip) that may affect knee pain evaluation
- History of autoimmune disease
- Active infection requiring parenteral antibiotics
- History of psychiatric disorder or epilepsy
- History of cell therapy or gene therapy to target joint
- Dermatological disease at injection site or site deemed unsuitable for injection
- Cognitive impairment or dementia preventing informed consent
- Any other condition that makes the subject unsuitable for study participation per investigator judgment
- Uncontrolled type 1 or type 2 diabetes mellitus (HbA1c >7%)
- Abnormal laboratory values at screening:
- ALT, AST, BUN, or serum creatinine >2× upper limit of normal
- Body Mass Index (BMI) ≥32 kg/m²
- Radiographic evidence of definite loss of patellofemoral joint space
- Moderate to severe joint effusion confirmed by positive patellar tap test or equivalent
- Intra-articular injections (e.g., hyaluronic acid) into knee joint within 6 months
- Engaged in high-intensity aerobic or heavy anaerobic exercise that may affect the knee joint
- Ligament instability of Grade II or higher in target knee (Grade 0: none; Grade I: 0-5 mm; Grade II: 5-10 mm; Grade III: >10 mm)
- Pregnant or breastfeeding women
- Participation in another clinical trial within 4 weeks
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial aims to evaluate and compare the efficacy and safety of CartiPRO, an approved intra-articular atelocollagen injection, versus Synovian injection for the relief of knee pain in patients with knee osteoarthritis. The investigational device is administered intra-articularly, with a second injection given 24 weeks after the first dose. Primary and secondary endpoints include changes in pain scores (VAS), functional assessments (WOMAC, SF-36), and safety evaluations over a 36-week period.
The 2 groups in the trial
- Study GroupTreatment being tested
Group applied with CartiPRO
Treatment: CartiPRO
- Control groupExisting treatment, for comparison
Group applied with Synovian®
Treatment: Synovian®
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long-term Efficacy and Safety of CartiPRO Injection to Alleviate Knee Pain in Patients With Osteoarthritis and/or Diverse Cartilage Defects: a Multicenter, Single-blind, Randomized, Non-inferiority, Sponsor Initiated Trial
- Record updated
- 5 October 2026